ADCYAP1 and migraine disorder: In a preclinical model of migraine, glibenclamide attenuated cephalic hypersensitivity in spontaneous trigeminal allodynic rats [11], and glibenclamide almost completely inhibited cephalic hypersensitivity and pain responses following sensitization with CGRP, PACAP-38, or levcromakalim [10, 21].